Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sanofi SA (NYSE:SNY)

43.16
Delayed Data
As of Feb 17
 -0.38 / -0.87%
Today’s Change
36.81
Today|||52-Week Range
44.50
+6.73%
Year-to-Date
Could Celgene Have Another Billion-Dollar Blockbuster on Its Hands?
11:53am / MotleyFool.com - Paid Partner Content
Top Analyst Reports for Morgan Stanley, GM & Prudential
Feb 10 / Zacks.com - Paid Partner Content
Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta
Feb 17 / TheStreet.com - Paid Partner Content
Pharma Stock Roundup: Allergan, GSK Top 4Q Earnings, Praluent Breather for Sanofi
Feb 10 / Zacks.com - Paid Partner Content
DexCom Is a Great Healthcare Stock to Buy Now
Feb 15 / TheStreet.com - Paid Partner Content
Alnylam Pharmaceuticals, Inc. Presents Progress -- Investors Dig It
Feb 09 / MotleyFool.com - Paid Partner Content
Towerview Llc Buys Syngenta AG, Time Warner, EVINE Live, Sells International Business...
Feb 15 / GuruFocus News - Paid Partner Content
Regeneron (REGN) Misses on Q4 Earnings & Sales, View Bleak
Feb 09 / Zacks.com - Paid Partner Content
Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More
Feb 15 / Zacks.com - Paid Partner Content
Alnylam (ALNY) Q3 Loss Narrower than Expected, Revenues Rise
Feb 09 / Zacks.com - Paid Partner Content
Amgen Looking to Broaden Leukemia Drug Blincyto's Label
Feb 15 / Zacks.com - Paid Partner Content
Regeneron (REGN) Q4 Earnings: Will the Stock Disappoint?
Feb 08 / Zacks.com - Paid Partner Content
Mylan Shares Unchanged as Kaleo Releases EpiPen Competitor
Feb 14 / TheStreet.com - Paid Partner Content
Drug Stock Q4 Earnings to Watch on Feb 8: AGN, GSK & More
Feb 07 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Morgan Stanley, General Motors, Prudential Financi...
Feb 13 / Zacks.com - Paid Partner Content
Why Merrimack Pharmaceuticals Got Crushed 23.8% in January
Feb 06 / MotleyFool.com - Paid Partner Content
Flu Death Rates Just Hit the Epidemic Threshold, but This Is the Real Shocker
Feb 11 / MotleyFool.com - Paid Partner Content
Better Buy: Agenus Inc. vs. Alnylam Pharmaceuticals, Inc.
Feb 06 / MotleyFool.com - Paid Partner Content